Mizuho lowered the firm’s price target on Medtronic (MDT) to $120 from $125 and keeps an Outperform rating on the shares. The firm adjusted estimates and price targets for several names in its medical devices and diagnostics coverage ahead of Q1 earnings from the group.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $106 from $108 at Evercore ISI
- Medtronic price target lowered to $110 from $117 at Citi
- Medtronic: MiniMed IPO Dilution and Diabetes Spin-Off Limit Near-Term Upside, Justifying Hold Rating
- Medtronic price target lowered to $95 from $105 at Stifel
- Medtronic price target lowered to $115 from $125 at Argus